Skip to content

Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in Children.

Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01883596
Enrollment
70
Registered
2013-06-21
Start date
2012-10-31
Completion date
2016-12-31
Last updated
2015-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical Ventilation for More Than 48 Hours.

Brief summary

To determine the efficacy of prophylaxis with 0.12% chlorhexidine gluconate compared with placebo to prevent ventilator associated pneumonia in children admitted to a pediatric critical care unit.

Detailed description

Randomised controlled trial to determine the efficacy of 0.12% chlorhexidine gluconate compared with placebo to prevent ventilator associated pneumonia in children admitted to a pediatric critical care unit.

Interventions

Bexident® (0.12% chlorhexidine solution)

DRUGPlacebo

7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.

Sponsors

Sinaloa Pediatric Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children aged 1 month to 18 years admitted to the intensive care unit. * Intubated for more than 48 hours.

Exclusion criteria

* Clinical or radiological diagnosis of pneumonia previous to the endotracheal intubation. * Allergy to chlorhexidine. * Known immune deficiency. Elimination Criteria: * Transfer to another hospital.

Design outcomes

Primary

MeasureTime frame
Incidence of ventilator associated pneumoniaParticipants will be followed for the duration of intensive care unit stay, an expected average of 2 weeks

Secondary

MeasureTime frame
MortalityParticipants will be followed for the duration of intensive care unit stay, an expected average of 2 weeks
Days of mechanical ventilationFrom date of randomization until the date of death or date of extubation, whichever comes first, an expected average of 2 weeks
Length of stayFrom date of randomization until the date of death or date of discharge from the intensive care unit, an expected average of 2 weeks

Countries

Mexico

Contacts

Primary ContactJesus J Martinez, MD
jjmtz64@hotmail.com+52 (667) 7139004
Backup ContactLuz I Zamudio, MD
zluz_isabel@hotmail.com+52 (667) 7164686

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026